TITLE

OPTIMAL CONTROL OF COMBINED THERAPY IN A SINGLE STRAIN HIV-1 MODEL

AUTHOR(S)

Garira, Winston; Musekwa, Senelani D.; Shiri, Tinevimbo

PUB. DATE

April 2005

SOURCE

Electronic Journal of Differential Equations;2005, Vol. 2005, p1

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Highly active antiretroviral therapy (HAART) is administered to symptomatic human immunodeficiency virus (HIV) infected individuals to improve their health. Various administration schemes are used to improve patients' lives and at the same time suppressing development of drug resistance, reduce evolution of new viral strains, minimize serious side effects, improve patient adherence and also reduce the costs of drugs. We deduce an optimal drug administration scheme useful in improving patients' health especially in poor resourced settings. In this paper we use the Pontryagin's Maximum Principle to derive optimal drug dosages based on a mathematical dynamical model. We use methods of optimal control to determine optimal controls analytically, and then use the Runge-Kutta scheme of order four to numerically simulate different therapy effects. We simulate the different effects of a drug regimen composed of a protease inhibitor and a nucleoside reverse transcriptase inhibitor. Our results indicate that for highly toxic drugs, small dosage sizes and allowing drug holidays make a profound impact in both improving the quality of life and reducing economic costs of therapy. The results show that for drugs with less toxicity, continuous therapy is beneficial.

ACCESSION #

19513691

Tags: ANTIRETROVIRAL agents;  HIV (Viruses);  REVERSE transcriptase;  ANTIVIRAL agents;  DNA polymerases

 

Related Articles

• HIV-1 RT Nonnucleoside Inhibitors and Their Interaction with RT for Antiviral Drug Development. Zhigang Zhou; Xin Lin; Madura, Jeffry D. // Infectious Disorders - Drug Targets;Dec2006, Vol. 6 Issue 4, p391 

  Non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) have become an inherent component of highly active antiretroviral therapy (HAART) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections. One of the most serious problems associated with NNRTIs is that the virus...

• Recent Advances in the Research of HIV-1 RNase H Inhibitors. Fang Yu; Xinyong Liu; Peng Zhan; De Clercq, Erik // Mini Reviews in Medicinal Chemistry;Oct2008, Vol. 8 Issue 12, p1243 

  Reverse transcription is a crucial step in the life cycle of human immunodeficiency virus type 1 (HIV-1). In this process, multiple functional enzymes including RNA-dependent DNA polymerase, DNA-dependent DNA polymerase and RNase H are indispensable. The RNase H functions to degrade RNA of the...

• New therapeutic strategies for raltegravir. Garrido, Carolina; Soriano, Vincent; de Mendoza, Carmen // Journal of Antimicrobial Chemotherapy (JAC);Feb2010, Vol. 65 Issue 2, p218 

  Raltegravir (Isentress®) is the first approved HIV integrase inhibitor. Agents in this class target a different viral enzyme compared with agents inhibiting reverse transcriptase and protease. A wide number of patients are currently susceptible to integrase inhibitors, including heavily...

• The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy. Rosenblum, Michael; Deeks, Steven G.; van der Laan, Mark; Bangsberg, David R. // PLoS ONE;2009, Vol. 4 Issue 9, p1 

  Background: We hypothesized that the percent adherence to antiretroviral therapy necessary to maintain HIV suppression would decrease with longer duration of viral suppression. Methodology: Eligible participants were identified from the REACH cohort of marginally housed HIV infected adults in...

• In silico Mutational analysis and Drug interaction studies of HIV Reverse Transcriptase. Pinnamaneni, Rajasekhar; Anil, Nateshan; Subramanyam, Kondeti; Thirumavalavan, M.; Subramanyam, Koona // International Journal of Computer Applications;8/15/2012, Vol. 52, p9 

  Human immunodeficiency virus is a retrovirus that causes acquired immunodeficiency syndrome, a condition in humans in which the immune system begins to fail, leading to life threatening opportunistic infections. Reverse transcriptase inhibitors are class of antiretroviral drugs used to treat HIV...

• Current Developments in the Synthesis and Biological Activity of HIV-1 Double-Drug Inhibitors. Muhanji, Clare I.; Hunter, Roger // Current Medicinal Chemistry;2007, Vol. 14 Issue 11, p1207 

  A combination of different HIV inhibitors into a single molecular entity is a strategy that is growing in popularity in HIVchemotherapy research. The high levels of resistance elicited by both nucleoside and non-nucleoside reverse transcriptase inhibitors has prompted the design of double-drugs...

• Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and Prognosis. Sungkanuparph, Somnuek; Overton, E. Turner; Seyfried, Warren; Groger, Richard K.; Fraser, Victoria J.; Powderly, William G. // Clinical Infectious Diseases;11/1/2005, Vol. 41 Issue 9, p1326 

  Background. Intermittent episodes of detectable human immunodeficiency virus (HIV) viremia (hereafter referred to as "blips") are generally not predictive of subsequent virologic failure. Limited data are available for patients treated with nonnucleoside reverse-transcriptase inhibitor...

• The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-na�ve (HIV1)-infected individuals in Casablanca, Morocco. Bakhouch, Khadija; Oulad-Lahcen, Ahd; Bensghir, Rajae; Blaghen, Mohamed; Elfilali, Kamal Marhoum; Ezzikouri, Sayeh; Abidi, Omar; Hassar, Mohamed; Wakrim, Lahcen // Journal of Infection in Developing Countries;2009, Vol. 3 Issue 5, p380 

  Background: The widespread use of antiretroviral agents and the growing occurrence of HIV-1 strains resistant to these drugs have given rise to serious concerns regarding the transmission of resistant viruses to newly infected persons, which may reduce the efficacy of a first-line antiretroviral...

• Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. Antonio Rivero; Jos� A. Mira; Juan A. Pineda // Journal of Antimicrobial Chemotherapy (JAC);Mar2007, Vol. 59 Issue 3, p342 

  Liver toxicity is one of the most relevant adverse effects of antiretroviral therapy. Within the non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz can be considered a safer drug for the liver than nevirapine. In fact, the frequency of severe increased liver enzymes in patients...

Read the Article